

Appendix: Patient Group Conflict of Interest Declaration

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it. NO
2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it. A volunteer helped collate the data.
3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

Company
July 2017 - Astra Zeneca. \$█K honorarium and travel expenses for Elisabeth Baugh and Kelly Grover to attend the AZ International BRCA Advisory Meeting in the U.K.
March 2018 – Astra Zeneca. Sponsorship for Canadian Conference on Ovarian Cancer Research
April 2018 – Hoffman LaRoche. Sponsorship for Canadian Conference on Ovarian Cancer Research
May 2018 – Astra Zeneca. Program funding
November 2018 – Astra Zeneca. \$█K honorarium and travel expenses for Marilyn Sapsford to attend the AZ Olaparib Ovarian Cancer National Advisory Board Meeting in Montreal
February 2019 – Astra Zeneca. Program funding

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Marilyn Sapsford
 Position: Manager, National Programs
 Patient Group: Ovarian Cancer Canada
 Date: May 2, 2019